Burak Cem – VP & General Manager, Novo Nordisk Turkey
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Address: Nispetiye Caddesi, Akmerkez, E3 Blok, Kat:7 Etiler, Istanbul, Turkey 34335, Turkey
Tel: +90 212 3854040
Web: http://www.novoturk.com/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in 190 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Providing solutions mainly in Diabetes and Haemophilia
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Would you like to provide our international readers with a brief introduction into Novo Nordisk’s Turkish affiliate? As you may know, Novo Nordisk has a rich history of over 85…
Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans…
M. Sonay Gürgen, chairman of the board and general manager of Selçuk Ecza Deposu, Turkey’s largest pharma distributory, offers his insider take on the pharmaceutical value chain in Turkey, the…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist…
Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry…
Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces…
Dr Orhan Mutlu Topal, general manager at Emre Ecza Ilac, offers an insider take on the Turkish vaccine industry, the challenges on the horizon for the Turkish pharmaceutical sector, and the…
Cem Kolak, founder and managing director of BL Turkey, the only Turkish Third Party Logistics (3PL) firm 100 percent dedicated to the biopharmaceutical and life sciences sectors, leverages his pioneering…
Meri Istiroti, group coordinator of Liv Hospital Group, shares the hospital’s success story since its beginning in 2013 to becoming a leading private healthcare institution dedicated to service, quality, and…
Emin Çakmak, chairman of the Turkish Healthcare Travel Council, offers deep insights into the healthcare travel industry and how it stretches beyond the commonly used term of “medical tourism”. Çakmak…
Elif Çelik, executive vice president of the Healthcare Division of Eczacıbaşı Group, explains the rationale behind the group’s divestment of its generics arm and its new strategy to establish itself…
Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the…
See our Cookie Privacy Policy Here